Artwork

Content provided by Citeline. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Citeline or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

ADDF's Karen Harris: Investing in Alzheimer's Like a VC

24:38
 
Share
 

Manage episode 492161176 series 2877522
Content provided by Citeline. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Citeline or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
How is venture philanthropy revolutionizing Alzheimer's drug discovery? We sit down with Karen Harris, CFO at the Alzheimer's Drug Discovery Foundation, to explore their game-changing approach to funding early-stage research. With $370M+ awarded to 765+ programs globally, the ADDF operates like a VC firm—using convertible debt and preferred equity to accelerate breakthrough treatments. Topics: Venture philanthropy vs traditional grants Shift from amyloid to combination therapies Blood-based biomarkers & precision medicine NIH funding cuts impact on research ecosystem Karen brings 20+ years investment banking experience to discuss how strategic capital is changing Alzheimer's research.
  continue reading

1538 episodes

Artwork
iconShare
 
Manage episode 492161176 series 2877522
Content provided by Citeline. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Citeline or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
How is venture philanthropy revolutionizing Alzheimer's drug discovery? We sit down with Karen Harris, CFO at the Alzheimer's Drug Discovery Foundation, to explore their game-changing approach to funding early-stage research. With $370M+ awarded to 765+ programs globally, the ADDF operates like a VC firm—using convertible debt and preferred equity to accelerate breakthrough treatments. Topics: Venture philanthropy vs traditional grants Shift from amyloid to combination therapies Blood-based biomarkers & precision medicine NIH funding cuts impact on research ecosystem Karen brings 20+ years investment banking experience to discuss how strategic capital is changing Alzheimer's research.
  continue reading

1538 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play